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ABSTRACT
The aim of present study was to formulate the sustained release 
floating tablets of Cephalexin (CPl) by direct compression 
method and optimized by Box-behnken response surface 
Methodology (rsM). a computer aided optimization technique 
was employed to investigate the formulation design by Box-
behnken rsM (design expert software version 8.0.7.1) to 
study the effect of the concentration of various polymer 
blends on the property of CPl gastroretentive floating tablets 
like floating lag time (Flt) and cumulative percent drug 
release (%Cdr). The independent variables investigated 
were polymeric concentrations (X1) and dependent variables 
were Flt (Y1), %Cdr (Y2) in 0.1n hCl (ph 1.2) buffer. 
results from precompression evaluation indicated that all 
the 17 and optimized formulation F18 were complied with 
the pharmacopoeial limits and post compression parameters 
were also gave satisfactory results. The predicted value for Flt 
and %Cdr obtained from software was compared with the 
experimental value of Flt and %Cdr of optimized formulation 
F18. It was observed that the obtained experimental results for 
optimized formulation were in very close agreement with the 
predicted values and also the optimized formulation gave good 
Flt and %Cdr when compared to the 17 formulations.
Keywords: Cephalexin; design expert software; Floating 
tablets; Optimization; response surface Methodology.
1. INTRODUCTION
Gastro retentive technology is playing a major role in 
revolutionizing the future of gastric retention in the 
pharmaceutical industry. The gastro retentive floating drug 
delivery system can be used as an alternative to conventional 
dosage forms for the class of drugs which undergoes intestinal 
or enzymatic degradation and generally, those drugs are 
acidic in nature (1). drug absorption in the GI tract is a 
highly variable procedure and gastro retentive drug delivery 
systems prolong gastric retention of the dosage forms, extend 
the time for drug absorption thereby reduces drug wastage, 
improve bioavailability and solubility of drug which is less 
soluble in the high ph environment (2). For gastric retention, 
floating drug delivery system is considered to be a potential 
approach and considerable research has been done on CPl 
floating tablets (3-7). 
CPl, a β-lactam antibiotic, is a broad-spectrum antibiotic for 
the treatment of wide variety of bacterial infections, including 
urinary tract infections and respiratory tract infections (3). It 
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is a lipophilic weak acid with pKa values of 4.5 and is stable 
in gastric conditions but degrades in intestinal conditions, 
hence a gastro retentive dosage form would be essential to 
ensure better drug delivery (4). CPl has higher absorption 
in proximal region of the gastrointestinal tract and lesser 
bioavailability (35%) mainly due to its instability in intestine 
and its narrow absorption window at the upper GI tract 
(5). This suggests that CPl is an ideal candidate for gastro 
retentive drug delivery system which prolongs the gastric 
residence time of the drug, providing prolonged drug release 
in upper gastro intestinal tract, where absorption of CPl is 
well confined.
The main objective of the present study was to formulate and 
optimize the sustained release gastro retentive floating tablets 
of CPl by direct compression method using Box-behnken 
response surface methodology. 
2. MATERIALS AND METHODS
2.1 Materials 
CPl was purchased from Orchid Chemicals and 
Pharmaceuticals ltd., India. hydroxy Propyl Methyl 
Cellulose (hPMC K4M) obtained from strides acrolabs, 
India, Cetyl alcohol (Ca) from loba chemie, India, sodium 
Carboxy Methyl Cellulose (sCMC) from Fisher scientific, 
India, Microcrystalline cellulose (MCC) from rolex chemical 
industries, India, sodium lauryl sulphate (sls) and sodium 
bicarbonate (sBC) from Yarrow chemicals, India, talc and 
Magnesium stearate (Ms) from s.d. Fine chem., India.     
2.2 FTIR studies
The drug-excipients compatibility was determined by KBr 
disc (pellet) method using FtIr spectrophotometer (Bruker, 
usa). The discs of pure drug and its physical mixtures were 
prepared and scanned from 4000 to 400 cm-1. The obtained 
spectra of pure drug and spectra of its physical mixtures were 
compared to know the possible drug-excipients interactions.
2.3 Experimental design of floating tablets of CPL
The factors like hPMC K4M, Ca and sBC were identified 
as critical formulation factors based on their effect or role 
on final dosage form from existing studies (3-7) and any 
variation in those factors shows a variable response on the 
dosage form. hence, the careful optimization of these factors 
is essential to obtain a better response of the developed dosage 
form. In the present investigation, independent formulation 
variables evaluated were X1: Polymeric concentrations and 
dependent variables investigated were Y1: Flt in 0.1n hCl 
(ph 1.2), Y2: % drug release in 0.1n hCl (ph 1.2) buffer at 
the end of 8 h. seventeen different formulation batches of 
floating tablets were evaluated to determine the potential 
effect of those independent variables on dependent variables 
(8). From the existing works, the minimum and maximum 
effective concentrations of those variables were entered into 
the software; thereby it was designed 17 formulations with 
different polymeric concentrations (table 1). 
Table 1. Formulation of CPl gastro retentive floating tablets
Ingredients
Quantity per tablrt (mg/tablet)
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 F17
CPl 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250
hPMC K4M 145 145 135 135 145 145 135 155 135 145 145 145 155 145 155 155 145
Ca 40 50 50 40 40 40 40 30 30 30 40 50 40 40 40 50 30
sBC 40 30 40 30 40 40 50 40 40 30 40 50 50 40 30 40 50
sCMC 35 35 35 35 35 35 35 35 35 35 35 35 35 35 35 35 35
MCC 23.5 23.5 23.5 43.5 23.5 23.5 23.5 23.5 43.5 43.5 23.5 3.5 3.5 23.5 23.5 3.5 13
sls 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5
talc 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5
Ms 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5
total weight 550 550 550 550 550 550 550 550 550 550 550 550 550 550 550 550 550
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2.4 Preparation of CPL floating tablets
tablets containing 250 mg of CPl were prepared according to 
the design depicted in table 1 by direct compression method. 
The excipients were chosen after the comprehensive drug 
excipient interaction studies and those were namely release 
retarding polymer (s) like hPMC K4M, Ca and sCMC, sBC 
(gas generating agent), sls and MCC (filler) were passed 
through sieve no.60, separately. Mixing of the ingredients 
was carried out by using a mortar and pestle for 10 min. 
lubricant (Magnesium stearate) and glidant (talc) previously 
passed through sieve no. 60 were added to the mixture and 
mixing was continued for additional 5 min. Finally, 550 mg 
of each mixture was weighed and fed manually in to the die 
of a 10 station tablet punching machine using 12 mm round 
shaped punches to produce the required tablets (rIMeK 
rotary tablet Punching machine, India). The hardness was 
adjusted to 7 kg/cm2. 
2.5 Evaluation studies
2.5.1 Precompression evaluation studies
The powder blends were evaluated for the precompression 
parameters like bulk density, tapped density, compressibility 
index (Carr’s Index), hausner’s ratio and angle of repose (9-
10).
2.5.2 Post compression evaluation studies
The tablets were evaluated for finished product quality control 
tests like thickness, weight variation, hardness, friability and 
drug content uniformity (11-12). 
2.5.3 Tablet floating behavior
The floating behavior of the tablets was visually determined 
in triplicate, according to the Flt method. Briefly, a tablet 
was placed in a glass beaker containing 100 ml of 0.1n hCl 
(ph 1.2) and maintained in a water bath at 37±0.5ºC, thereby 
the floating time was measured (13-14).
2.5.4 Swelling studies 
The extent of swelling is measured in terms of % of weight 
gained by the tablet. One tablet from each formulation was 
weighed (w1) and kept in glass beaker containing 100 ml of 
0.1n hCl (ph 1.2) buffer. at the end of the specified time 
intervals, tablets were withdrawn from the glass beaker 
and therefore the excess buffer was blotted with the tissue 
paper by taking care to avoid the surface erosion from tablet 
and swollen tablet was then reweighed (w2) (15).  The % of 
weight gained by the tablet was calculated by using following 
formula as.                        
2.5.5 In-vitro dissolution studies
In-vitro dissolution study of CPl was performed using usP 
dissolution apparatus, type II (Paddle method) (lab India 
8 basket dissolution apparatus, India) at 37ºC ± 0.5ºC and 
the paddle was set to rotate at a speed of 50 rpm. The tablets 
were placed in the dissolution apparatus containing 900 ml 
of 0.1n hCl (ph 1.2) buffer as dissolution medium. samples 
were withdrawn (10 ml) and replaced with an equal amount 
of fresh dissolution medium at particular time intervals, 
samples were immediately filtered through whatmann 
filter paper and diluted with the dissolution media. The 
absorbances of these diluted samples were noted at λmax 256 
nm using uV-Visible spectrophotometer (lab India 1700 
uV-Visible spectrophotometer, India) (16-17).                     
2.6 Kinetics studies 
The release kinetics of the drug was described by fitting the 
obtained in-vitro dissolution data into various kinetic models 
like zero order, first order, higuchi’s and Korsmeyer-Peppas 
models (18-19). 
3. RESULTS AND DISCUSSION
3.1 FTIR Studies
FtIr spectrum of pure drug and its physical mixtures 
were studied. The major Ir peaks observed for pure CPl at 
1758.22, 3272.98, 1689.58, 1454.85 and 1594.85 cm-1 were 
mainly because of C=O stretching, n-h stretching, C=O 
stretching, C=C stretching and n-h bending respectively. In 
the present study, it was observed that there were no major 
shifts in its individual characteristic peaks; hence, it indicates 
that there were no incompatibility issues between drug and 
polymers used (Figure 1).
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3.2 Precompression evaluation
The powder blends of formulations F1-F17 have the bulk 
density ranged from 0.492±0.0087 to 0.512±0.0056 and 
tapped density from 0.587±0.012 to 0.618±0.0080. The 
compressibility index values less than 10, 11-15, 16-20, 21-
25, 26-31, 32-37 and greater than 38 indicates excellent, 
good, fair, possible, poor, very poor and very very poor 
flow respectively and powder blends of all the formulations 
[F1-F17] developed in the formulation development phase 
were found to be possessing the good to fair flowability i.e. 
13.549 to 19.626 %. The ideal hausner’s ratio values of 1.0-
1.11, 1.12-1.18, 1.19-1.25, 1.26-1.34, 1.35-1.45, 1.46-1.59 and 
greater 1.60 indicates excellent, good, fair, possible, poor, 
very poor and very very poor flow respectively and powder 
blends of all the formulations were found to be possessing 
the fair to passable flowability i.e. 1.156 to 1.244. The ideal 
angle of repose values of less than 25, 25-30, 30-40 and 
greater than 40 indicates excellent, good, passable and very 
poor respectively and the experimental values of all the 
formulations were ranged from 26.581º to 30.504º indicates 
good to passable flowability (table 2).
Figure 1. FtIr spectra CPl with excipients. a) FtIr spectra of pure CPl, B) FtIr spectra of CPl + hPMC K4M, C) FtIr 
spectra of CPl + Cetyl alcohol, d) FtIr spectra of CPl + sBC, e) FtIr spectra of CPl + sCMC, F) FtIr spectra of CPl + 
MCC, G) FtIr spectra of CPl +sls, h) FtIr spectra of CPl optimized formulation (F-18)
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3.3 Post compression evaluation
weight variation test revealed that all the formulations [F1-
F17] developed in the formulation development phase were 
complied with the official limits (if the tablet weight is greater 
than 324 mg, the maximum difference allowed is ±10 mg) 
and ranged from 550.333±0.288 mg to 551±0.5 mg. hardness 
of all the formulations was ranged from 6.65±0.060 kg/cm2 to 
6.943±0.260 kg/cm2 and thickness ranged from 4.46±0.026 
to 4.496±0.050 mm. The ideal friability value is less than 
1% and the obtained experimental values were ranged from 
0.427±0.082 % to 0.894±0.016 %, hence the friability test was 
satisfied. The maximum difference allowed for drug content is 
±5 and it was ranged from 97.254±1.113% to 99.999±4.043% 
(table 3).
3.4 Floating behavior 
On immersion in 0.1 n hCl (ph 1.2) at 37 ºC, it expands and 
CO2 was formed within the tablets thereby floated and remained 
buoyant without disintegration. Formulations consists of high 
concentration of hPMC K4M (F-8) showed good Flt and 
tFt, which might be due to the rapid hydration of the polymer, 
thereby it forms gelatinous layer when exposed to aqueous 
medium. This gelatinous layer prevents the escape of CO2 
from dosage form thereby decreases the density which leads to 
floating of tablets within a short period of time (table 3) (19).
Table 2. evaluation of precompression parameters
Formulation Bulk density
(gm/cc)
Tapped density
(gm/cc)
Carr’s index
(I)
Hausner’s ratio Angle of repose
(0)
CPL
(pure drug)
0.59±0.012 0.76±0.021 21.72±1.99 1.27±0.032 36.17±0.64
F1 0.53±0.006 0.61±0.008 13.54±0.33 1.15±0.002 30.50±1.03
F2 0.50±0.004 0.62±0.014 19.202.34± 1.23±0.036 28.82±2.84
F3 0.49±0.008 0.61±0.013 19.63±1.64 1.24±0.025 26.58±0.54
F4 0.49±0.009 0.60±0.013 18.171.68± 1.22±0.025 28.17±0.98
F5 0.53±0.006 0.61±0.008 13.54±0.15 1.15±0.002 30.501.03±
F6 0.53±0.006 0.61±0.008 13.54±0.15 1.15±0.002 30.501.03±
F7 0.49±0.009 0.60±0.007 16.96±0.78 1.20±0.011 27.211.08±
F8 0.49±0.046 0.59±0.013 17.813.25± 1.21±0.048 27.701.89±
F9 0.51±0.005 0.61±0.013 16.442.09± 1.19±0.030 30.411.60±
F10 0.51±0.005 0.60±0.016 15.80±2.77 1.18±0.039 25.90±1.07
F11 0.53±0.006 0.61±0.008 13.540.15± 1.15±0.002 30.501.03±
F12 0.51±0.005 0.61±0.008 14.64±1.03 1.17±0.014 28.03±0.96
F13 0.50±0.005 0.58±0.012 14.26±2.71 1.16±0.036 28.50±1.167
F14 0.53±0.006 0.61±0.008 13.54±0.15 1.15±0.002 30.50±1.03
F15 0.50±0.009 0.61±0.013 18.84±2.88 1.22±0.044 28.812.08±
F16 0.50±0.005 0.58±0.019 14.973.60± 1.17±0.049 29.061.05±
F17 0.50±0.005 0.59±0.013 15.60±2.69 1.18±0.038 26.89±1.05
all the results were expressed in mean ± sd (n=3)
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3.5 Swelling study
The swelling index was calculated with respect to the time 
and results were represented in table 4. as the time increases, 
the swelling index was also increased, because weight gain 
by tablet was increased proportionally with rate of hydration. 
later on, it decreased gradually due to dissolution of 
outermost gelled layer of the tablet into dissolution medium 
(20). water uptake studies showed that the formulation 
with higher percentage of hPMC K4M imbibed more water 
and was swollen to greater extent than formulation with 
low percentage of hPMC K4M. swelling index of all the 
formulations increased upto 6th h and subsequently it was 
decreased at 8th h. The swelling index of the formulation 
F8 was found to be maximum throughout the study (table 
14). The swelling index of all the formulations is increases 
with increase in the concentration of hPMC K4M and 
decreases with increase in the concentration of Ca due to its 
hydrophobic nature (21). Incorporation of varying amounts 
of sBC in the formulation had shown no significant impact 
on the swelling index. Formulations (F3, F4, F7 and F9) 
with low concentration of hPMC K4M swelled instantly 
which did not persist due to subsequent erosion which was 
supported by the kinetic studies where the r2 value was better 
to the higuchi model except F9. 
Table 3. evaluation of post compression parameters
Formulation  Weight variation (mg)
Hardness (kg/
cm2) Thickness (mm)
Friability
(%) % Drug content TFT (h)
FLT
(sec)
F1 550.5±0.50 6.73±0.21 4.46±0.032 0.50±0.04 98.33±1.48 ˃ 12 15.81
F2 550.3±0.28 6.84±0.17 4.46±0.026 0.89±0.01 99.11±0.72 ˃ 12 14.69
F3 550.6±0.28 6.83±0.18 4.49±0.050 0.65±0.10 98.62±1.79 ˃ 12 8.17
F4 550.8±1.04 6.94±0.26 4.47±0.020 0.54±0.07 98.82±1.06 ˃ 12 9.72
F5 550.5±0.50 6.73±0.21 4.46±0.032 0.50±0.04 98.33±1.48 ˃ 12 15.81
F6 550.5±0.50 6.73±0.21 4.46±0.032 0.50±0.04 98.33±1.48 ˃ 12 15.81
F7 550.6±0.28 6.66±0.08 4.46±0.032 0.53±0.13 97.54±2.73 ˃ 12 9.44
F8 551.0±0.50 6.73±0.12 4.46±0.013 0.53±0.07 97.25±1.11 ˃ 12 19.63
F9 550.3±0.57 6.70±0.17 4.45±0.020 0.63±0.04 98.72±2.44 ˃ 12 12.52
F10 550.3±0.28 6.73±0.11 4.46±0.025 0.57±0.11 99.99±4.04 ˃ 12 16.22
F11 550.5±0.50 6.73±0.21 4.46±0.032 0.50±0.04 98.33±1.48 ˃ 12 15.81
F12 550.3±0.28 6.85±0.09 4.46±0.015 0.49±0.05 99.41±2.05 ˃ 12 9.89
F13 550.5±0.52 6.69±0.14 4.47±0.020 0.44±0.07 99.503.53± ˃ 12 20.25
F14 550.5±0.50 6.73±0.21 4.46±0.032 0.50±0.04 98.33±1.48 ˃ 12 15.81
F15 550.6±0.28 6.76±0.13 4.49±0.050 0.42±0.08 98.72±2.94 ˃ 12 22.88
F16 550.60.57± 6.65±0.06 4.48±0.030 0.58±0.05 98.03±0.89 ˃ 12 19.94
F17 550.8±0.57 6.66±0.16 4.47±0.020 0.63±0.07 99.60±0.61 ˃ 12 14.54
all the results were expressed in mean ± sd (n=3)
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3.6 In-vitro drug release studies
From the release profiles, it was concluded that the variation 
in concentrations of polymer from F1 to F17 had variable 
effect on drug release. The effect of hPMC K4M and Ca 
could be observed at constant sCMC level. hPMC K4M 
with higher molecular weight forms gel of higher viscosity 
(4000cps) compared to sCMC (not less than 2000cps). 
Formulations containing lower limit of hPMC K4M showed 
early release in dissolution medium but as increase in the 
concentration of Ca causes decrease in the drug release due 
to its water repelling capacity and the formulation F9 showed 
maximum drug release of 96.35% (table 5).
Table 4. Mean swelling indices of all formulations
Formulation At 1st h
At 
2nd h
At 
3rd h
At 
4th h
At 
5th h
At 
6th h
At 
7th h
At 
 8th h
F1 55.57±0.93 87.75±0.45 107.57±0.27 110.90±0.18 114.12±0.45 125.51±0.27 131.00±0.11 121.63±0.18
F2 58.24±0.27 83.69±0.27 100.24±0.58 111.81±0.36 118.30±0.55 120±0.36 112.77±0.27 107.33±0.45
F3 54.60±0.27 73.21±0.45 85.51±0.45 88.90±0.65 120.12±0.37 121.21±0.13 116.33±0.33 109.15±0.45
F4 60±0.36 71.03±0.37 96.36±0.36 98.18±0.18 107.33±0.27 114.66±0.37 107.44±0.41 100.18±0.48
F5 55.57±0.93 87.75±0.45 107.57±0.27 110.90±0.18 114.12±0.45 125.51±0.27 131.00±0.11 121.63±0.18
F6 55.57±0.93 87.75±0.45 107.57±0.27 110.90±0.18 114.12±0.45 125.51±0.27 131.09±0.181 121.63±0.18
F7 54.54±0.36 72.66±0.45 87.33±0.27 94.66±0.55 126.24±0.73 130.96±0.27 123.69±0.45 114.36±0.65
F8 62.12±0.27 80.06±0.63 103.51±0.37 110.96±0.27 131.09±0.65 132.84±0.55 123.81±0.48 116.30±0.45
F9 53.15±0.45 74.60±0.45 94.54±0.36 104.06±0.45 118.18±0.36 120.66±0.89 118.60±0.37 112.78±0.45
F10 56.78±0.37 84.06±0.45 102.72±0.12 112.78±0.27 114.66±0.37 125.44±0.11 119.93±0.45 108.54±0.10
F11 55.57±0.93 87.75±0.45 107.57±0.27 110.90±0.18 114.12±0.45 125.55±0.27 131.09±0.18 121.63±0.18
F12 60.18±0.18 87.45±0.18 102.24±0.45 105.39±0.45 120.06±0.27 125.55±0.38 123.69±0.45 116.12±0.27
F13 56.60±0.27 89.15±0.27 105.87±0.45 107.21±0.45 129.09±0.36 138.66±0.47 136.30±0.45 131.15±0.27
F14 55.57±0.93 87.75±0.45 107.57±0.27 110.90±0.18 114.12±0.45 125.55±0.27 131.09±0.18 121.63±0.18
F15 57.45±0.18 92.36±0.48 102.18±0.36 105.51±0.45 122.30±0.45 123.77±0.15 129.09±0.58 120.06±0.27
F16 51.09±0.18 74.60±0.27 104±0.48 105.57±0.37 107.21±0.27 118.66±0.47 124.06±0.37 118.72±0.54
F17 54.54±0.18 85.51±0.45 103.75±0.37 107.27±0.54 111.03±0.55 114.88±0.68 151.09±0.48 145.69±0.27
all the results were expressed in mean ± sd (n=3)
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F5-F11, F14 and F17, the r2 value of zero order is very near 
to one than other kinetic models. Thus, it can be said that 
the drug release follows zero-order kinetics. The r2 value 
of formulations F3, F12, F13, F15 and F16 was found to 
very near to one and they follow First order kinetics. The 
‘n’ values of Korsmeyer-Peppas model of the formulations 
(F1, F2 and F4-F17) have the ‘n’ value in the range of 0.45-
0.89, thus they follow the non-Fickian transport and the ‘n’ 
value of formulation F-3 is below 0.45 which indicates the 
Fickian transport (table 6).
3.7 In-vitro drug release kinetics
The mechanism of drug release for the dissolution data was 
determined by finding the r2 value for each kinetic model 
viz. zero order, first order, higuchi’s, and Korsmeyer-
Peppas models. For tablets, an ‘n’ value near to 0.45 
indicates diffusion controlled drug release and an ‘n’ 
value 0.89 or near to 1 indicates swelling-controlled drug 
release. The intermediate values of n between 0.45 and 1 
can be regarded as an indicator for both the phenomena 
(anomalous transport). For the formulations F1, F2, F4, 
Table 6. In-vitro drug release kinetics of all formulations
Formulation
Zero order First order Higuchi Korsmeyer-Peppas
Drug release mechanism
r2 r2 r2 Diffusion exponent (n)
F1 0.968 0.940 0.929 0.777 non-Fickian transport
F2 0.967 0.899 0.906 0.729 non-Fickian transport
F3 0.625 0.949 0.974 0.393 Fickian transport
F4 0.847 0.816 0.949 0.507 non-Fickian transport
F5 0.968 0.940 0.929 0.777 non-Fickian transport
F6 0.968 0.940 0.929 0.777 non-Fickian transport
F7 0.967 0.899 0.906 0.729 non-Fickian transport
F8 0.934 0.934 0.955 0.638 non-Fickian transport
F9 0.909 0.773 0.936 0.605 non-Fickian transport
F10 0.892 0.873 0.940 0.572 non-Fickian transport
F11 0.968 0.940 0.929 0.777 non-Fickian transport
F12 0.839 0.970 0.990 0.538 non-Fickian transport
F13 0.898 0.917 0.956 0.566 non-Fickian transport
F14 0.968 0.940 0.929 0.777 non-Fickian transport
F15 0.889 0.957 0.975 0.552 non-Fickian transport
F16 0.851 0.943 0.971 0.532 non-Fickian transport
F17 0.947 0.943 0.934 0.690 non-Fickian transport
3.8 Formulation development
In the development of any pharmaceutical formulation, 
a very important issue is to design a formulation with the 
optimized quality. The rsM has been ordinarily used for the 
designing and optimization of the various pharmaceutical 
formulations, which needs minimum experimentation. Thus, 
it is less time consuming and cost effective than the other 
typical ways of formulating the dosage forms. Based on the 
design of experiments, rsM encompasses the generation of 
polynomial equations of the response over the experimental 
domain to determine the optimum formulation(s). a 
computer aided optimization technique was employed to 
investigate the formulation design by using Box-behnken 
design expert software version 8.0.7.1. and studies the effect 
of concentration of various polymer blends used on the 
properties like floating lag time (Flt), cumulative percent 
drug release (%Cdr) of CPl gastroretentive floating tablets. 
3.9 Optimization
The Flt and %Cdr data (table 17) was entered into the 
generated design model and then the software generates 
model graphs to interpret and evaluate the given data to find 
out the best response. response 1 (Flt in 0.1n (ph 1.2) 
hCl) and 2 (%Cdr in 0.1n (ph 1.2) hCl) were analyzed 
by anOVa for response surface linear Model-1 and 2 
respectively. 
3.9.1 Response 1: FLT in 0.1N HCl (pH 1.2)
The Model F-value of 39.24 implies the model is significant. 
There is only a 0.01% chance that a “Model F-Value” could 
occur in large due to noise.
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3.9.2 Response 2: %CDR in 0.1N HCl (pH 1.2)
The Model F-value of 40.51 implies the model is significant. 
There is only a 0.01% chance that a “Model F-Value” could 
occur in large due to noise. all responses were fitted to 
linear models as suggested by design expert software 8.0.7.1. 
The F value for Flt, %Cdr were found to be 39.24, 40.51 
respectively indicating that the models are significant. The 
values of Prob ˃ F were found to be < 0.0001 for all responses 
indicating that the models are significant (table 7). The 
contour and response surface plots for all responses of all 
formulation factors are shown in figure 2. with the help of 
these 3d and contour graphs, the point at which maximum 
predicted response shown was recorded. with the help 
of factors tool, the concentrations of critical factors were 
adjusted in the software to show the maximum predicted 
response (table 8).
Table 7. anOVa for response surface linear Model-1 & 2
Source df* Model-1 Model-2 Significance
F Value Prob > 
F**
F Value Prob > 
F**
Model 9 39.24 < 0.0001 40.51 <0.0001 significant
hPMC K4M 1 297.30 < 0.0001 291.46 <0.0001 significant
Ca 1 16.91 0.0045 17.34 0.0042 significant
sBC 1 14.28 0.0069 10.03 0.0158
lack of Fit 3 Valid
Pure error 4 Valid
*a recommendation is a minimum of 3 lack of fit df and 4 df for 
pure error.This ensures a valid lack of fit test. 
**Values of “Prob > F” less than 0.0500 indicate model terms are 
significant and Values greater than 0.1000 indicate the model terms 
are not significant. 
Figure 2. Correlation between experimental and predicted values. a) Contour plot of Flt in 0.1 hCl (ph 1.2) buffer, B) 
Contour plot of % Cdr, C) 3d Graph for Flt in 0.1 hCl (ph 1.2) buffer, d) 3d Graph for % Cdr.
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3.9.3 Point Prediction and optimization results
to optimize all the responses with different targets, a 
multicriteria decision approach (a numerical optimization 
technique by the desirability function and a graphical 
optimization technique by the overlay plot) was used. The 
optimized formulation was obtained by applying constrains 
on dependent variable responses and independent variables. 
Constrains were Flt in 0.1n (ph 1.2) hCl; % Cdr at 8 h 
and these constrains are common for all the formulations. 
The recommended concentrations of the independent 
variables were calculated by the design expert software from 
the above plots which has the highest desirability near to 
1.0. The predicted concentrations of critical factors (hPMC 
K4M-136.08 mg, Ca-30.11 mg, sBC-49.57 mg) generated 
by software showed the Flt of 7.856 sec and drug release of 
99.15% (table 8). Based on these predictions, an optimized 
formulation has been prepared with the predicted variable 
factors and analyzed for the %Cdr and Flt.
4. CONCLUSION
From the experimental data, it could be concluded that a 
successful gastro retentive floating drug delivery system 
for CPl has been developed by direct compression method 
using Box-behnken rsM. statistically optimized formulation 
containing CPl showed promising results and there exist a 
scope for in-vivo evaluation using suitable animal models 
and increase in bioavailability may be confirmed.
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Table 8. Maximum predicted response (two-sided  Confidence =  95% (n = 1)) and Percentage Prediction   error of the 
Optimized formulation 
Response Prediction SD SE Predicted 95% PI low 95% PI high Experimental 
Value
Percentage Prediction   
Error
Flt 7.856 sec 0.8786 1.350    1.9741 8.36027 8.041sec -2.166
%Cdr 99.151 % 1.0350 1.5907 93.3951 101.458 97.691% -1.495
3.9.4 Evaluation and validation of the optimized 
formulation
By taking the predicted factors into consideration, a 
formulation has been developed. The prepared formulation 
was evaluated for the precompressional and post 
compressional parameters. Precompression parameters like 
angle of repose, hausner’s ratio and Carr’s index were found to 
be within the prescribed limits. Post compressionl parameters 
like the weight variation, thickness, drug content, swelling 
index, Flt, In-vitro dissolution studies were also studied. The 
tablets produced with the predicted concentrations of critical 
factors showed drug release of 97.691% in 8 h and Flt of 
8.041 sec (table 9) and the results are in very close agreement 
with the model predictions. drug release from the optimized 
formulation F18 followed zero order release (r2 = 0.916) with 
non-fickian type of diffusion mechanism (n=0.505). The 
relative error (%) between the predicted and experimental 
values confirms the predictability and validity of the model.
Table 9. evaluation of optimized formulation (F18)
Formulation
Precompression parameters
Bulk density
(gm/cc)*
Tapped density
(gm/cc)*
Carr’s index
(I)* Hausner’s ratio
* Angle of repose*
(0)
F18
0.50±0.002 0.58±0.003 13.68±1.05 1.15±0.001 29.32±0.36
               Post compression parameters
Weight variation 
(mg) *
Hardness (kg/
cm2) *
Thickness 
(mm) *
Friability
(%)*
% Drug content* TFT (h) FLT
(sec)
550.5±0.5 6.72±0.22 4.486±0.03 0.628±0.07 99.117±1.63 >12 8.041 
Swelling study*
At 
1st h
At 
2nd h
At 
3rd h
At 
4th h
At 
5th h
At 
6th h
At 
7th h
At 
 8th h
53.39±
1.74
87.09±
0.72
108.10±
1.01
111.15±
0.55
114.30±
0.81
126.12±
1.14
131.51±
0.81
122.12
0.63±
In-vitro drug release*
0 h 0.5 h 1 h 2 h 4 h 6 h 8h
0 20.68 ±0.64 38.77 ±0.84 49.41 
±1.18
60.12 ±1.71 79.460.74± 97.69 ±0.55
Kinetic studies 
Zero order 
(r2)
First 
order (r2)
Higuchi (r2) Korsmeyer-Peppas (n) Drug release mechanism
0.916 0.857 0.985 0.964 non-Fickian transport
*all the results were expressed in mean ± sd (n=3)
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Sefaleksin  içeren midede kalış süresini uzatan yüzen 
tabletlerde uzatılmış salınım özelliklerinin geliştirilmesi ve 
istatistiksel değerlendirilmesi
ÖZ
Bu çalışmada,  sefaleksin (CPl) içeren, uzatılmış salınım 
özelliğine sahip, midede kalış süresini uzatan yüzen tabletlerin 
direkt basım yöntemi ile formülasyonu ve Box-behnken uyarıcı 
Yüzey Yöntemine (rsM) göre optimizasyonu amaçlanmıştır. 
Bilgisayar ortamında Box-behnken rsM (design expert 
sotware version 8.0.7.1.) yöntemi kullanılarak; çeşitli polimer 
karışımlarının derişimlerinin, CPl içeren midede kalış 
süresini uzatan yüzen tabletlerin yüzme gecikme zamanı 
(Flt) ve kümülatif ilaç salınım yüzdesi (%Cdr) üzerine 
etkileri çalışılmıştır. Üzerinde çalışılan bağımsız değişken; 
polimer derişimleri (X1), bağımlı değişkenler ise 0,1 n 
hCl (ph 1,2) tamponu içerisinde Flt (Y1) ve %Cdr (Y2) 
olarak belirlenmiştir. Basım öncesi çalışmalarda, hazırlanan 
17 formülasyonun ve optimize edilen formülasyon olan 
F18’in farmakopede belirtilen gerekliliklerle uyumlu olduğu 
belirlenirken basım sonrası parametrelerin de kabul edilebilir 
olduğu tespit edilmiştir. Bilgisayar ortamında tahmin edilen 
Flt ve %Cdr verileri, optimize edilen formülasyon olan F18’in 
deneysel yöntemlerle elde edilen Flt ve %Cdr sonuçları 
ile karşılaştırılmıştır. F18’in deneysel sonuçlarının bilgisayar 
ortamında yapılan tahminler ile yüksek oranda benzerlik 
gösterdiği ve diğer 17 formülasyonla karşılaştırıldığında F18’in 
daha iyi Flt ve %Cdr değerlerine sahip olduğu görülmüştür.
Anahtar kelimeler: sefaleksin; design expert Yazılımı; Yüzen 
tabletler; Optimizasyon; uyarıcı Yüzey Yöntemi.
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